Table 1.
Origin and status of IC products assessed.
| Product | Market Authorization Holder | Country | Status |
|---|---|---|---|
| Yisaipu | Shanghai CP Guojian Pharmaceutical Co, Ltd | China | Marketed as a recombinant human tumor necrosis factor-α receptor II – IgG Fc fusion protein.18 |
| Etanar® | Lafrancol (Laboratorio Franco-Colombiano SA) | Colombia | Described as a new biologic type rhTNFR:Fc.19 |
| Etacept | Cipla | India | Marketed as a biosimilar of etanercept.20 |
| Infinitam | Probiomed | Mexico | Marketed as a biosimilar of Enbrel.21 |
| Altebrel™ | Aryogen | Iran | Marketed as a biosimilar for etanercept.22 |
| Intacept | Intas | India | Marketed as a biosimilar for etanercept.23 |
| Qiangke | Shanghai Celgen Biopharma | China | Marketed as a new biologic.24 |